Arbutus Biopharma Corp Contracts Revenue (Deprecated 2018-01-31)
Arbutus Biopharma Corp (ABUS) reported Contracts Revenue (Deprecated 2018-01-31) of $682.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Income Statement › Other Income
us-gaap:ContractsRevenue · last filed 2018-03-16
CAD
| Period end | Contracts Revenue (Deprecated 2018-01-31) 12 month |
|---|---|
| 2012-12-31 | 12.10M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | 16.12M CAD 20-F · filed 2013-03-27 |
| 2010-12-31 | 14.92M CAD 20-F · filed 2013-03-27 |
| 2009-12-31 | 13.83M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Contracts Revenue (Deprecated 2018-01-31) 3 month | Contracts Revenue (Deprecated 2018-01-31) 6 month | Contracts Revenue (Deprecated 2018-01-31) 9 month | Contracts Revenue (Deprecated 2018-01-31) 12 month | Contracts Revenue (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|
| 2017-12-31 | $682.00K 10-K · filed 2018-03-16 | ||||
| 2017-06-30 | $318.00K 10-Q · filed 2017-08-03 | $336.00K 10-Q · filed 2017-08-03 | $339.00K derived: sum of 3 quarters · filed 2018-03-16 | $426.00K derived: sum of 4 quarters · filed 2018-03-16 | |
| 2017-03-31 | $18.00K 10-Q · filed 2017-05-04 | $21.00K derived: sum of 2 quarters · filed 2018-03-16 | $108.00K derived: sum of 3 quarters · filed 2018-03-16 | $140.00K derived: sum of 4 quarters · filed 2018-03-16 | |
| 2016-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $90.00K derived: sum of 2 quarters · filed 2018-03-16 | $122.00K derived: sum of 3 quarters · filed 2018-03-16 | $229.00K 10-K · filed 2018-03-16 | |
| 2016-09-30 | $87.00K 10-Q · filed 2016-11-03 | $119.00K derived: sum of 2 quarters · filed 2017-08-03 | $226.00K 10-Q · filed 2016-11-03 | $3.07M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2016-06-30 | $32.00K 10-Q · filed 2017-08-03 | $139.00K 10-Q · filed 2017-08-03 | $2.99M derived: sum of 3 quarters · filed 2018-03-16 | $6.02M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2016-03-31 | $107.00K 10-Q · filed 2017-05-04 | $2.95M derived: sum of 2 quarters · filed 2018-03-16 | $5.99M derived: sum of 3 quarters · filed 2018-03-16 | $8.30M derived: sum of 4 quarters · filed 2018-03-16 | |
| 2015-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $5.88M derived: sum of 2 quarters · filed 2018-03-16 | $8.19M derived: sum of 3 quarters · filed 2018-03-16 | $11.71M 10-K · filed 2018-03-16 | $13.31M 10-K · filed 2016-03-09 |
| 2015-09-30 | $3.04M 10-Q · filed 2016-11-03 | $3.04M 10-Q · filed 2015-11-05 | $8.87M 10-Q · filed 2016-11-03 | $12.19M derived: sum of 4 quarters · filed 2017-03-22 | |
| 2015-06-30 | $2.31M 10-Q · filed 2016-08-04 | $5.83M 10-Q · filed 2016-08-04 | $9.16M derived: sum of 3 quarters · filed 2017-03-22 | $12.73M derived: sum of 4 quarters · filed 2017-03-22 | |
| 2015-03-31 | $3.52M 10-Q · filed 2016-05-04 | $6.85M derived: sum of 2 quarters · filed 2017-03-22 | $10.43M derived: sum of 3 quarters · filed 2017-03-22 | $11.57M derived: sum of 4 quarters · filed 2017-03-22 | |
| 2014-12-31 | $3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22 | $6.91M derived: sum of 2 quarters · filed 2017-03-22 | $8.05M derived: sum of 3 quarters · filed 2017-03-22 | $11.74M 10-K · filed 2017-03-22 | |
| 2014-09-30 | $3.58M 10-Q · filed 2015-11-05 | $3.58M 10-Q · filed 2015-11-05 | $8.41M 10-Q · filed 2015-11-05 | $10.90M derived: sum of 4 quarters · filed 2016-03-09 | |
| 2014-06-30 | $1.14M 10-Q · filed 2015-08-07 | $4.83M 10-Q · filed 2015-08-07 | $7.32M derived: sum of 3 quarters · filed 2016-03-09 | $10.28M derived: sum of 4 quarters · filed 2016-03-09 | |
| 2014-03-31 | $3.69M 10-Q · filed 2015-05-06 | $6.18M derived: sum of 2 quarters · filed 2016-03-09 | $9.14M derived: sum of 3 quarters · filed 2016-03-09 | $11.98M derived: sum of 4 quarters · filed 2016-03-09 | |
| 2013-12-31 | $2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $5.45M derived: sum of 2 quarters · filed 2016-03-09 | $8.29M derived: sum of 3 quarters · filed 2016-03-09 | $10.43M 10-K · filed 2016-03-09 | $10.42M 6-K · filed 2014-03-06 |
| 2013-09-30 | $2.96M 10-Q · filed 2014-11-07 | $5.80M derived: sum of 2 quarters · filed 2014-11-07 | $7.94M 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | $2.84M 10-Q · filed 2014-08-14 | $4.97M 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | $2.13M 10-Q · filed 2014-05-14 | ||||
| 2012-12-31 | $12.11M 10-K · filed 2015-03-13 | $1.00M 20-F · filed 2013-03-27 | |||
| 2011-12-31 | $16.31M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |